Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh